156 related articles for article (PubMed ID: 35652401)
1. Efficacy and Safety of Lobaplatin-TACE in the Treatment of Primary Hepatocellular Carcinoma: A Retrospective Study.
Lu H; Zheng C; Liang B; Xiong B
Anticancer Agents Med Chem; 2023; 23(4):461-469. PubMed ID: 35652401
[TBL] [Abstract][Full Text] [Related]
2. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
Maeda N; Osuga K; Higashihara H; Tomoda K; Mikami K; Nakazawa T; Nakamura H; Tomiyama N
Cardiovasc Intervent Radiol; 2012 Feb; 35(1):82-9. PubMed ID: 21203761
[TBL] [Abstract][Full Text] [Related]
3. TACE with dicycloplatin in patients with unresectable hepatocellular carcinoma: a multicenter randomized phase II trial.
Zhu HD; Li X; Ji JS; Huang M; Shao GL; Lu J; Zhao XY; Li HL; Yang ZQ; Tu JF; Zhou JM; Zeng CH; Teng GJ
Eur Radiol; 2022 Nov; 32(11):7335-7343. PubMed ID: 35776182
[TBL] [Abstract][Full Text] [Related]
4. Uninfluenced alpha-fetoprotein and treatment of liver primary carcinoma by lobaplatin in combination with 5-fluorouracil and doxorubicin via chemoembolization and transarterial chemoembolization.
Chen Y; Li W; Yang Q; Chen L; Zeng C
Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):48-51. PubMed ID: 32538746
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety analysis of dexamethasone-lipiodol emulsion in prevention of post-embolization syndrome after TACE: a retrospective analysis.
Lu H; Zheng C; Liang B; Xiong B
BMC Gastroenterol; 2021 Jun; 21(1):256. PubMed ID: 34116638
[TBL] [Abstract][Full Text] [Related]
6. Transarterial chemoembolization with miriplatin plus epirubicin in patients with hepatocellular carcinoma.
Tawada A; Chiba T; Ooka Y; Kanogawa N; Saito T; Motoyama T; Ogasawara S; Suzuki E; Kanai F; Yoshikawa M; Yokosuka O
Anticancer Res; 2015 Jan; 35(1):549-54. PubMed ID: 25550601
[TBL] [Abstract][Full Text] [Related]
7. Effect of camrelizumab plus transarterial chemoembolization on massive hepatocellular carcinoma.
Zhang S; Zhao Y; He L; Bo C; An Y; Li N; Ma W; Guo Y; Guo Y; Zhang C
Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101851. PubMed ID: 34923180
[TBL] [Abstract][Full Text] [Related]
8. A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma.
Yodono H; Matsuo K; Shinohara A
Anticancer Drugs; 2011 Mar; 22(3):277-82. PubMed ID: 21360850
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma.
He M; Li Q; Shen J; Tan G; Li Q; Lai J; Wei W; Zhang Y; Zou R; Chen M; Guo R; Shi M
Cancer Med; 2019 Aug; 8(9):4200-4213. PubMed ID: 31207163
[TBL] [Abstract][Full Text] [Related]
10. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
[No Abstract] [Full Text] [Related]
11. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial.
Li QJ; He MK; Chen HW; Fang WQ; Zhou YM; Xu L; Wei W; Zhang YJ; Guo Y; Guo RP; Chen MS; Shi M
J Clin Oncol; 2022 Jan; 40(2):150-160. PubMed ID: 34648352
[TBL] [Abstract][Full Text] [Related]
12. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
Wu B; Zhou J; Ling G; Zhu D; Long Q
World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
[TBL] [Abstract][Full Text] [Related]
13. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis.
Takayasu K; Arii S; Ikai I; Kudo M; Matsuyama Y; Kojiro M; Makuuchi M;
AJR Am J Roentgenol; 2010 Mar; 194(3):830-7. PubMed ID: 20173167
[TBL] [Abstract][Full Text] [Related]
14. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
Zhang ZS; Li HZ; Ma C; Xiao YD
BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
[TBL] [Abstract][Full Text] [Related]
15. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
Tang J; Huang Z; Xu J; Lv Q; Wang P
Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
[TBL] [Abstract][Full Text] [Related]
16. Lobaplatin-TACE combined with radioactive 125I seed implantation for treatment of primary hepatocellular carcinoma.
Peng S; Yang QX; Zhang T; Lu MJ; Yang G; Liu ZY; Zhang R; Zhang FJ
Asian Pac J Cancer Prev; 2014; 15(13):5155-60. PubMed ID: 25040967
[TBL] [Abstract][Full Text] [Related]
17. Short-term efficacy of transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for hepatocellular carcinoma: comparison with conventional transarterial chemoembolization.
Morimoto M; Kobayashi S; Moriya S; Ueno M; Tezuka S; Irie K; Goda Y; Ohkawa S
Abdom Radiol (NY); 2017 Feb; 42(2):612-619. PubMed ID: 27624498
[TBL] [Abstract][Full Text] [Related]
18. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
[TBL] [Abstract][Full Text] [Related]
19. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.
Hu J; Bao Q; Cao G; Zhu X; Yang R; Ji X; Xu L; Zheng K; Li W; Xing B; Wang X
Cardiovasc Intervent Radiol; 2020 Jul; 43(7):996-1005. PubMed ID: 31974744
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study.
Lu H; Ye Q; Zheng C; Fan L; Xia X
BMC Cancer; 2023 Mar; 23(1):270. PubMed ID: 36964538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
